

United States Biosimilars Market Size, Share, and Analysis, By Product Type (Instruments, Reagents & Consumables, Software & Services), By Application (Clinical Diagnostics, Drug Discovery & Development, Patient Monitoring, Others), By End-User (Hospitals & Clinics, Diagnostic Laboratories, Pharmaceutical & Biotech Companies, Others) and Forecast 2026–2035

<https://marketpublishers.com/r/UA0A73256866EN.html>

Date: April 2026

Pages: 536

Price: US\$ 4,710.00 (Single User License)

ID: UA0A73256866EN

Abstracts

United States Biosimilars Market was valued at USD \$1.44 billion in 2026 and is projected to reach USD \$6.39 billion by 2035, registering a CAGR of 18.0% across the forecast period. The United States Biosimilars Market continues to expand as deep capital markets, early-adopter enterprise buyers, and a dense innovation ecosystem reshape demand across the value chain.

“Instruments is projected to hold the largest share of the United States Biosimilars Market through 2035.” This segment continues to gain traction owing to strong existing adoption, favorable total cost of ownership, and vendors bundling advisory and integration services around it to lengthen customer relationships within the United States Biosimilars Market.

“Hospitals & Clinics is likely to remain the leading end-user segment of the United States Biosimilars Market.” Budget cycles among these buyers are lengthening as procurement teams weigh total cost of ownership more heavily than upfront price, reshaping how vendors package and price united states biosimilars offerings for 2026-2035.

“United States continues to lead adoption within the united states biosimilars

market.” United States benefits from deep capital markets, early-adopter enterprise buyers, and a dense innovation ecosystem, reinforcing its position as a priority market for vendors through 2035.

Market Segmentation:

By Product Type: Instruments, Reagents & Consumables, Software & Services

By Application: Clinical Diagnostics, Drug Discovery & Development, Patient Monitoring, Others

By End-User: Hospitals & Clinics, Diagnostic Laboratories, Pharmaceutical & Biotech Companies, Others

This report on the United States Biosimilars Market combines primary and secondary research, triangulated using a bottom-up and top-down approach. Secondary research (~55% of data inputs) drew on paid industry databases, company filings, regulatory data, and trade association statistics. Primary research (~45%) consisted of structured expert interviews with senior executives, product managers, and channel partners across the value chain, used to validate assumptions and surface trends not visible in published data.

Primary interviews substantiate the findings: By Company Type – Tier 1 39%, Tier 2 30%, Tier 3 31%; By Designation – C-level 32%, Directors 27%, Others 41%; By Region – United States 100% (single-market study; sub-segment splits detailed in Section 11).

Key Players active in the United States Biosimilars Market:

Pfizer Inc.

Roche Holding AG

Johnson & Johnson

Novartis AG

Medtronic plc

GE HealthCare

Siemens Healthineers

Strategies observed across these players span product innovation, capacity expansion, and partnerships with channel and technology allies to defend share as new entrants emerge.

Research Coverage: The study defines, segments, and forecasts the United States Biosimilars Market by product type, application, end-user, with qualitative insight into regulatory context, supply-chain dynamics, pricing trends, and competitive positioning.

Key Benefits of Buying the Report: (1) Identify growth pockets aligned with 2026-2035 demand signals across the United States Biosimilars Market; (2) Understand the drivers and restraints shaping adoption through the forecast period; (3) Size opportunities in underpenetrated segments and geographies; (4) Anticipate execution risks tied to regulatory shifts and procurement-cycle timing.

Market Developments: The period 2026-2035 is characterized by consolidation among established players, rising investment from new entrants targeting adjacent price tiers, and growing buyer preference for vendors offering integrated, service-attached united states biosimilars solutions.

Fatpos Global – Why You Should Purchase This United States Biosimilars Market Report: Access decision-grade analytics built on triangulated primary and secondary research; benchmark competitors with comparative scorecards; and translate insights into sales narratives and partnership plays that improve win rates.

Contents

1. EXECUTIVE SUMMARY

- 1.1. Market Share Overview
- 1.2. Business Trends
- 1.3. United States Biosimilars Market: Post-Pandemic & Macroeconomic Outlook
- 1.4. Key Trends
- 1.5. Segmentation Snapshot

2. RESEARCH METHODOLOGY

- 2.1. Research Objective
- 2.2. Research Approach
- 2.3. Data Sourcing and Methodology
- 2.4. Primary Research
- 2.5. Secondary Research
 - 2.5.1. Paid Sources
 - 2.5.2. Public Sources
- 2.6. Market Size Estimation and Data Triangulation

3. MARKET CHARACTERISTICS

- 3.1. Market Definition
- 3.2. United States Biosimilars Market: Regulatory & Policy Impact
- 3.3. Key Segmentations
- 3.4. Key Developments
- 3.5. Allied Industry Data

4. UNITED STATES BIOSIMILARS MARKET – INDUSTRY INSIGHTS

- 4.1. Industry Segmentation
- 4.2. Supply Chain / Value Chain Analysis
- 4.3. Industry Ecosystem & Channel Analysis
- 4.4. Innovation & Sustainability

5. MACROECONOMIC INDICATORS

6. RECENT DEVELOPMENTS

7. MARKET DYNAMICS

- 7.1. Introduction
- 7.2. Growth Drivers
- 7.3. Market Opportunities
- 7.4. Market Restraints
- 7.5. Market Trends

8. RISK ANALYSIS

9. MARKET ANALYSIS

- 9.1. Porter's Five Forces
- 9.2. PEST Analysis
 - 9.2.1. Political
 - 9.2.2. Economic
 - 9.2.3. Social
 - 9.2.4. Technological

10. UNITED STATES BIOSIMILARS MARKET

- 10.1. Overview
- 10.2. Historical Analysis (2021-2025)
 - 10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast

11. UNITED STATES BIOSIMILARS MARKET SIZE & FORECAST 2026A-2035F

- 11.1. Overview
- 11.2. Key Findings
- 11.3. Market Segmentation
 - 11.3.1. By Product Type
 - 11.3.1.1. Instruments
 - 11.3.1.1.1. By Value (USD Million) 2026-2035F
 - 11.3.1.1.2. Market Share (%) 2026-2035F
 - 11.3.1.1.3. Y-o-Y Growth (%) 2026-2035F
 - 11.3.1.2. Reagents & Consumables
 - 11.3.1.2.1. By Value (USD Million) 2026-2035F
 - 11.3.1.2.2. Market Share (%) 2026-2035F

- 11.3.1.2.3. Y-o-Y Growth (%) 2026-2035F
- 11.3.1.3. Software & Services
 - 11.3.1.3.1. By Value (USD Million) 2026-2035F
 - 11.3.1.3.2. Market Share (%) 2026-2035F
 - 11.3.1.3.3. Y-o-Y Growth (%) 2026-2035F
- 11.3.2. By Application
 - 11.3.2.1. Clinical Diagnostics
 - 11.3.2.1.1. By Value (USD Million) 2026-2035F
 - 11.3.2.1.2. Market Share (%) 2026-2035F
 - 11.3.2.1.3. Y-o-Y Growth (%) 2026-2035F
 - 11.3.2.2. Drug Discovery & Development
 - 11.3.2.2.1. By Value (USD Million) 2026-2035F
 - 11.3.2.2.2. Market Share (%) 2026-2035F
 - 11.3.2.2.3. Y-o-Y Growth (%) 2026-2035F
 - 11.3.2.3. Patient Monitoring
 - 11.3.2.3.1. By Value (USD Million) 2026-2035F
 - 11.3.2.3.2. Market Share (%) 2026-2035F
 - 11.3.2.3.3. Y-o-Y Growth (%) 2026-2035F
 - 11.3.2.4. Others
 - 11.3.2.4.1. By Value (USD Million) 2026-2035F
 - 11.3.2.4.2. Market Share (%) 2026-2035F
 - 11.3.2.4.3. Y-o-Y Growth (%) 2026-2035F
- 11.3.3. By End-User
 - 11.3.3.1. Hospitals & Clinics
 - 11.3.3.1.1. By Value (USD Million) 2026-2035F
 - 11.3.3.1.2. Market Share (%) 2026-2035F
 - 11.3.3.1.3. Y-o-Y Growth (%) 2026-2035F
 - 11.3.3.2. Diagnostic Laboratories
 - 11.3.3.2.1. By Value (USD Million) 2026-2035F
 - 11.3.3.2.2. Market Share (%) 2026-2035F
 - 11.3.3.2.3. Y-o-Y Growth (%) 2026-2035F
 - 11.3.3.3. Pharmaceutical & Biotech Companies
 - 11.3.3.3.1. By Value (USD Million) 2026-2035F
 - 11.3.3.3.2. Market Share (%) 2026-2035F
 - 11.3.3.3.3. Y-o-Y Growth (%) 2026-2035F
 - 11.3.3.4. Others
 - 11.3.3.4.1. By Value (USD Million) 2026-2035F
 - 11.3.3.4.2. Market Share (%) 2026-2035F
 - 11.3.3.4.3. Y-o-Y Growth (%) 2026-2035F

12. UNITED STATES UNITED STATES BIOSIMILARS MARKET SIZE & FORECAST 2026A-2035F – REGIONAL BREAKDOWN

- 12.1. Overview
- 12.2. Key Findings
- 12.3. Market Segmentation
 - 12.3.1. By Product Type
 - 12.3.2. By Application
 - 12.3.3. By End-User

13. COMPETITIVE LANDSCAPE

- 13.1. Company Market Share, 2025
- 13.2. Key Player Overview
- 13.3. Key Stakeholders

14. COMPANY PROFILES

- 14.1. Pfizer Inc.
 - 14.1.1. Company Overview
 - 14.1.2. Financial Overview
 - 14.1.3. Key Product / Service Analysis
 - 14.1.4. Company Assessment
 - 14.1.4.1. Product Portfolio
 - 14.1.4.2. Key Clients
 - 14.1.4.3. Market Share
 - 14.1.4.4. Recent News & Development (Last 3 Yrs.)
 - 14.1.4.5. Executive Team
- 14.2. Roche Holding AG
- 14.3. Johnson & Johnson
- 14.4. Novartis AG
- 14.5. Medtronic plc
- 14.6. GE HealthCare
- 14.7. Siemens Healthineers
- 14.8. Abbott Laboratories
- 14.9. Thermo Fisher Scientific
- 14.10. Merck & Co.
- 14.11. Other Prominent Players

15. APPENDIX

16. CONSULTANT RECOMMENDATION

I would like to order

Product name: United States Biosimilars Market Size, Share, and Analysis, By Product Type (Instruments, Reagents & Consumables, Software & Services), By Application (Clinical Diagnostics, Drug Discovery & Development, Patient Monitoring, Others), By End-User (Hospitals & Clinics, Diagnostic Laboratories, Pharmaceutical & Biotech Companies, Others) and Forecast 2026–2035

Product link: <https://marketpublishers.com/r/UA0A73256866EN.html>

Price: US\$ 4,710.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/UA0A73256866EN.html>